Sunshine Biopharma, Inc.
SBFM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $335 | $324 | $5,163 | $7,740 |
| - Cash | $9,306 | $10,305 | $8,125 | $9,687 |
| + Debt | $855 | $929 | $936 | $952 |
| Enterprise Value | -$8,117 | -$9,053 | -$2,026 | -$994 |
| Revenue | – | $9,410 | $8,901 | $9,595 |
| % Growth | – | 5.7% | -7.2% | – |
| Gross Profit | – | $3,423 | $2,730 | $3,093 |
| % Margin | – | 36.4% | 30.7% | 32.2% |
| EBITDA | – | -$1,907 | -$1,155 | -$2,213 |
| % Margin | – | -20.3% | -13% | -23.1% |
| Net Income | – | -$1,771 | -$1,180 | -$2,158 |
| % Margin | – | -18.8% | -13.3% | -22.5% |
| EPS Diluted | – | -7.8 | -0.44 | -0.84 |
| % Growth | – | -1,672.7% | 47.6% | – |
| Operating Cash Flow | – | -$1,273 | -$1,714 | -$3,407 |
| Capital Expenditures | – | -$550 | -$212 | -$439 |
| Free Cash Flow | – | -$1,824 | -$1,926 | -$3,847 |